← Human Trials & Peer-Reviewed Studies
[EFFECT OF RECOMBINANT HUMAN GROWTH HORMONE ON ENDOTHELIALIZATION OF VASCULAR PROSTHESES].
Plain-language guide to PMID 26466482 (2015): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2009, patients.
Key Facts
- PMID
- 26466482
- Journal
- Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Zhang Z et al. (7 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Who Took Part
According to the abstract, 2009, patients were involved.
Between August 2007 and January 2009, 94 patients with lower extremity arteriosclerotic occlusive disease were treated.
Among them, 32 patients (34 limbs) who met the selection criteria were enrolled in this study.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
All cases were randomly divided into study group (16 cases, 18 limbs) and control group (16 cases, 16 limbs).
The patients with superficial femoral artery disease received above-knee femoro-popliteal prostheses bypass.
The patients who had combined abdominal-iliac artery disease received concurrent abdominal-femoral and femoro-popliteal prostheses bypass.
What Was Measured
The subject headings attached to it are Angioplasty, Arterial Occlusive Diseases, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation, Femoral Artery, Human Growth Hormone and Iliac Artery.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2009, patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery), a journal based in China.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.